Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the IUPAC name (6-[4-(aminomethyl)-2,6-dimethylphenoxy]-2-{[4-(aminomethyl)phenyl]amino}-5-bromopyrimidin-4-yl)methanol. It has been studied as a ligand and inhibitor in structural biology research involving reverse transcriptase enzymes. The molecule contains aminomethyl and dimethyl substitutions on phenoxy and phenyl rings attached to a brominated pyrimidinyl core with a methanol group. Its primary use appears to be as an experimental tool compound for biochemical or structural studies of reverse transcriptase, rather than as an approved pharmaceutical agent[8][2]. There is no evidence it has reached clinical development or approval for any therapeutic indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (6-[4-(aminomethyl)-2,6-dimethylphenoxy]-2-{[4-(aminomethyl)phenyl]amino}-5-bromopyrimidin-4-yl)methanol.